This week, world leaders are announcing a series of pledges to protect and sustainably use the world’s oceans. The pledges form the crowning achievement of the ‘High Level Panel for a Sustainable Ocean Economy’ a multinational group formed back in 2018.
The panel has sought to bring together research, published in a number of so-called ‘blue papers’ and special reports by scientists, policy- and legal-experts from around the world – all with the ear of 14 participating world leaders.
Erna Solberg, the prime minister of Norway, co-led the Panel. In this podcast, she speaks with Springer Nature’s editor-in-chief Philip Campbell about the panel’s work.
One year since the outbreak emerged in Wuhan, China says it has vaccinated nearly one million people against Covid-19. FRANCE 24 correspondent Charles Pellegrin says while the vaccines have yet to be fully approved for market, authorities have granted permission for their limited use on selected groups of the population.
Finding medicines that can kill cancer cells while leaving normal tissue unscathed is a Holy Grail of oncology research. In two new papers, scientists at UC San Francisco and Princeton University present complementary strategies to crack this problem with “smart” cell therapies—living medicines that remain inert unless triggered by combinations of proteins that only ever appear together in cancer cells.
Biological aspects of this general approach have been explored for several years in the laboratory of Wendell Lim, PhD, and colleagues in the UCSF Cell Design Initiative and National Cancer Institute– sponsored Center for Synthetic Immunology. But the new work adds a powerful new dimension to this work by combining cutting-edge therapeutic cell engineering with advanced computational methods.
For one paper, published September 23, 2020 in Cell Systems, members of Lim’s lab joined forces with the research group of computer scientist Olga G. Troyanskaya, PhD, of Princeton’s Lewis-Sigler Institute for Integrative Genomics and the Simons Foundation’s Flatiron Institute.
Using a machine learning approach, the team analyzed massive databases of thousands of proteins found in both cancer and normal cells. They then combed through millions of possible protein combinations to assemble a catalog of combinations that could be used to precisely target only cancer cells while leaving normal ones alone. In another paper, published in Science on November 27, 2020, Lim and colleagues then showed how this computationally derived protein data could be put to use to drive the design of effective and highly selective cell therapies for cancer.
“Currently, most cancer treatments, including CAR T cells, are told ‘block this,’ or ‘kill this,’” said Lim, also professor and chair of cellular and molecular pharmacology and a member of the UCSF Helen Diller Family Comprehensive Cancer Center. “We want to increase the nuance and sophistication of the decisions that a therapeutic cell makes.”
Over the past decade, chimeric antigen receptor (CAR) T cells have been in the spotlight as a powerful way to treat cancer. In CAR T cell therapy, immune system cells are taken from a patient’s blood, and manipulated in the laboratory to express a specific receptor that will recognize a very particular marker, or antigen, on cancer cells. While scientists have shown that CAR T cells can be quite effective, and sometimes curative, in blood cancers such as leukemia and lymphoma, so far the method hasn’t worked well in solid tumors, such as cancers of the breast, lung, or liver.
Cells in these solid cancers often share antigens with normal cells found in other tissues, which poses the risk that CAR T cells could have off-target effects by targeting healthy organs. Also, solid tumors also often create suppressive microenvironments that limit the efficacy of CAR T cells. For Lim, cells are akin to molecular computers that can sense their environment and then integrate that information to make decisions. Since solid tumors are more complex than blood cancers, “you have to make a more complex product” to fight them, he said.
Many schools closed in the spring, during the first wave of the coronavirus pandemic. Many opened in the fall. Staff Writer Jennifer Couzin-Frankel joins host Sarah Crespi to talk about what was learned in spring about how coronavirus spreads in schools that might help keep children safe as cases surge once again.
Also this week: What makes leaves fall off deciduous trees when they do—is it the short, cold nights? Or is the timing of so-called “leaf senescence” linked to when spring happens? Sarah talked to Constantin Zohner, a lead scientist at the Institute of Integrative Biology at ETH Zurich, about his tree leaf timing study. Sarah also spoke with commentary author Christy Rollinson, a forest ecologist at the Morton Arboretum, about how important these trees and the timing of their leaf drop is for climate change. In the books segment, host Kiki Sanford talks with Ruth DeFries about her book, What Would Nature Do? A Guide for Our Uncertain Times.
Scientists have finally confirmed the existence of a CNO cycle fusion reaction in the Sun, and why women’s contraception research needs a reboot.
In this episode:
00:47 Detection of CNO neutrinos
Since the 1930s it has been theorised that stars have a specific fusion reaction known as the CNO cycle, but proof has been elusive. Now, a collaboration in Italy report detection of neutrinos that show that the CNO cycle exists.
We discuss the search for the animal origin of SARS-CoV-2, with researchers raiding their freezer draws to see if any animals carry similar viruses, and the latest vaccine results.
21:50 Getting women’s contraception research unstuck
Since the 1960s there has been little progress on research into women’s contraceptives. This week in Nature, researchers argue that this needs to change.
As the weather gets colder and people head indoors, the risk of catching Covid-19 is rising. WSJ explains why air ventilation and filtration are one of our biggest defenses against the coronavirus this winter.
These days, about half of the protein the world’s population eats is from seafood. Staff Writer Erik Stokstad joins host Sarah Crespi to talk about how brand-new biotech and old-fashioned breeding programs are helping keep up with demand, by expanding where we can farm fish and how fast we can grow them.
Sarah also spoke with Jan Claesen, an assistant professor at the Cleveland Clinic’s Lerner Research Institute, about skin microbes that use their own antibiotic to fight off harmful bacteria. Understanding the microbes native to our skin and the molecules they produce could lead to treatments for skin disorders such as atopic dermatitis and acne. Finally, in a segment sponsored by MilliporeSigma, Science’s Custom Publishing Director and Senior Editor Sean Sanders talks with Timothy Cernak, an assistant professor of medicinal chemistry and chemistry at the University of Michigan, Ann Arbor, about retrosynthesis—the process of starting with a known chemical final product and figuring out how to make that molecule efficiently from available pieces.
Boomers Daily 